Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs.
about
Nonmyeloablative allogeneic hematopoietic cell transplantationImmunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell TransplantationRecruitment of CD8(+) T cells into bone marrow might explain the suppression of megakaryocyte apoptosis through high expression of CX3CR1(+) in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation.Cytomegalovirus in bone marrow cells correlates with cytomegalovirus in peripheral blood leukocytesImpact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplantValganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trialPrimary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation.Reduced-intensity conditioned allogeneic SCT in adults with AML.Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease.Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning.
P2860
Q26748780-CE8B55D5-1852-4BC6-B81A-ED397FECDF9FQ28078949-1355CC71-389C-4743-A06A-2DCDABD613E7Q33424130-A0D7CED7-2049-48A1-85BF-5261D7D44921Q33703469-58614BC0-BD09-4939-9680-CFE2B1F508AFQ34169235-0ABF7D10-1DCA-41D1-94CB-A852F39205A6Q35735525-BCEF2086-EA1D-4AEC-9DAB-1FADB20228ABQ35925091-C959B8BF-AB74-476E-9B48-1074E571FDC8Q36306393-5FBE0E5D-F864-4FC9-837C-8B098C77D3EFQ38366632-2BA6C028-F1B6-4BC8-AA20-D72207897DD5Q38405625-FBCCBD01-0F7E-499D-A28D-9DAA51159224Q40395771-0D8CAAE6-A3C1-4AFD-AFB6-A38549E9E61FQ43600843-386D95D9-7520-4E73-B376-F4F1CAA16A05
P2860
Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cytopenias after day 28 in all ...... nditions and myelotoxic drugs.
@ast
Cytopenias after day 28 in all ...... nditions and myelotoxic drugs.
@en
type
label
Cytopenias after day 28 in all ...... nditions and myelotoxic drugs.
@ast
Cytopenias after day 28 in all ...... nditions and myelotoxic drugs.
@en
prefLabel
Cytopenias after day 28 in all ...... nditions and myelotoxic drugs.
@ast
Cytopenias after day 28 in all ...... nditions and myelotoxic drugs.
@en
P2860
P50
P1433
P1476
Cytopenias after day 28 in all ...... nditions and myelotoxic drugs.
@en
P2093
Chris Davis
Hirohisa Nakamae
P2860
P304
P356
10.3324/HAEMATOL.2011.044966
P577
2011-08-31T00:00:00Z